Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ9-tetrahydrocannabinol in Sprague-Dawley rats

British Journal of Pharmacology

Volumn 172, Issue 7, 2015, Pages 1783-1791

  Taffe, Michael A ^a   Creehan, Kevin M ^a   Vandewater, Sophia A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; DRONABINOL; RIMONABANT; CANNABINOID RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DOSE RESPONSE; HYPOACTIVITY; HYPOTHERMIA; MALE; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RAT; TELEMETRY; THERMOREGULATION; TRANQUILIZING ACTIVITY; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; BODY TEMPERATURE; CANNABIDIOL; CANNABINOID RECEPTOR ANTAGONISTS; DRONABINOL; HYPOTHERMIA; MALE; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RATS, SPRAGUE-DAWLEY; TELEMETRY;

EID: 84924935509     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13024     Document Type: Article

References (43)

1. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA, (2013). The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71: 130-140.
2. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Belgrave BE, Bird KD, Chesher GB, Jackson DM, Lubbe KE, Starmer GA, et al. (1979). The effect of cannabidiol, alone and in combination with ethanol, on human performance. Psychopharmacology (Berl) 64: 243-246.
4. Brunt TM, van Genugten M, Honer-Snoeken K, van de Velde MJ, Niesink RJ, (2014). Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. J Clin Psychopharmacol 34: 344-349.
5. Burgdorf JR, Kilmer B, Pacula RL, (2011). Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend 117: 59-61.
6. Crean RD, Davis SA, Von Huben SN, Lay CC, Katner SN, Taffe MA, (2006). Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142: 515-525.
7. Crean RD, Davis SA, Taffe MA, (2007). Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques. Pharmacol Biochem Behav 87: 11-19.
8. Fernandes M, Schabarek A, Coper H, Hill R, (1974). Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38: 329-338.
9. Fernandez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA, (1997). Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem Pharmacol 53: 1919-1927.
10. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. (2001). The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
11. Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J, (2007). Acute effects of Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97: 109-117.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
13. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, et al. (2011). Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 218: 443-457.
14. Lichtman AH, Dimen KR, Martin BR, (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119: 282-290.
15. Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, et al. (2014). In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Delta-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav 124C: 40-47.
16. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
17. 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172: 737-753.
18. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO, (2007). Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692.
19. Miller ML, Creehan KM, Angrish D, Barlow DJ, Houseknecht KL, Dickerson TJ, et al. (2013). Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend 127: 248-253.
20. Morgan CJ, Schafer G, Freeman TP, Curran HV, (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 197: 285-290.
21. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42: 391-400.
22. Nava F, Carta G, Gessa GL, (2000). Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 66: 183-187.
23. Oreja-Guevara C, (2012). Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 12: 3-8.
24. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
25. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC, (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1-PL6.
26. Robson P, (2011). Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10: 675-685.
27. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM, (2008). Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18: 569-577.
28. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, et al. (2011). A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26: 224-236.
29. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, et al. (2010). Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes 34: 547-556.
30. Taffe MA, (2012a). Delta(9)tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. J Psychopharmacol 26: 1299-1306.
31. Taffe MA, (2012b). Delta9-tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience 201: 125-133.
32. Taffe MA, Lay CC, Von Huben SN, Davis SA, Crean RD, Katner SN, (2006). Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend 82: 276-281.
33. Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE, (1981). Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. Eur J Pharmacol 70: 219-224.
34. Turkanis SA, Karler R, (1986). Cannabidiol-caused depression of spinal motoneuron responses in cats. Pharmacol Biochem Behav 25: 89-94.
35. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, et al. (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
36. Wade DT, Makela P, Robson P, House H, Bateman C, (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10: 434-441.
37. Wiley JL, O'Connell MM, Tokarz ME, Wright MJ Jr, (2007). Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther 320: 1097-1105.
38. Winsauer PJ, Lambert P, Moerschbaecher JM, (1999). Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol 10: 497-511.
39. Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM, et al. (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS ONE 7: e44652.
40. Wright MJ Jr, Vandewater SA, Parsons LH, Taffe MA, (2013a). Δ9Tetrahydrocannabinol impairs reversal learning but not extra-dimensional shifts in rhesus macaques. Neuroscience 235: 51-58.
41. Wright MJ Jr, Vandewater SA, Taffe MA, (2013b). Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol 170: 1365-1373.
42. Zuardi AW, Teixeira NA, Karniol IC, (1984). Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269: 12-19.
43. Zuardi AW, Hallak JE, Crippa JA, (2012). Interaction between cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 219: 247-249.